

March 17, 1966

Dr. Necmettin Polvan  
Lamartin Cad. Burun Apt. 17/1  
Taksim - Talimhane  
Istanbul, Turkey

Dear Dr. Polvan:

In our last letter, you indicated that you were studying fluphenazine enanthate. After that, we wrote to the medical director of the Squibb Institute and asked whether our studies on fluphenazine decanoate would be parallel to your studies of fluphenazine enanthate. They have reviewed the experiences with the two prolonged forms of fluphenazine and called to tell me that it might be better for both our units to study the same compound. For this reason, they are shipping to their representative in Istanbul a supply of fluphenazine decanoate which is from the same batch that our supply has come. They did not know the name of their representative in Istanbul, but indicated that he would contact you and provide you with this material, if you decided to continue a parallel study.

We have also provided a new form for the behavioral rating scale which has been so helpful to us in our early studies. This form is so organized that the statistical operations are quite automatic. We will try to translate the English words into Turkish during the next few weeks and send you copies of the English form and our suggested Turkish translation. When you receive them, we would be grateful if you would make such editing as may be advisable and return it to us for final printing.

The study program with butaperazine has been discussed with the representative of A. H. Robins Co. They were interested and offered a provisional agreement to support the study, subject only to approval of the protocol. Turan and I will write this within the next few weeks and submit it to the company for their consideration.

I look forward to visiting with you this summer and to hearing more about the development of this study.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

MF:kp